Home Cart Sign in  
Chemical Structure| 16773-42-5 Chemical Structure| 16773-42-5

Structure of Ornidazole
CAS No.: 16773-42-5

Chemical Structure| 16773-42-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ornidazole is an antibiotic used to treat some protozoan infections and investigated for use in Crohn's disease after bowel resection.

Synonyms: Ro 7-0207; NSC 95075; Tiberal

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ornidazole

CAS No. :16773-42-5
Formula : C7H10ClN3O3
M.W : 219.63
SMILES Code : CC1=NC=C(N1CC(O)CCl)[N+]([O-])=O
Synonyms :
Ro 7-0207; NSC 95075; Tiberal
MDL No. :MFCD00057960
InChI Key :IPWKIXLWTCNBKN-UHFFFAOYSA-N
Pubchem ID :28061

Safety of Ornidazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary Sertoli cells 400 μg/mL 24 h Induce in vitro oligoasthenozoospermia and evaluate the effect of YC on cell survival. The results showed that YC significantly reversed the decline in cell viability caused by Ornidazole. Front Pharmacol. 2023 Apr 26;14:1056091.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Oligoasthenozoospermia model Oral 800 mg/kg Once daily for 30 days Induce in vivo oligoasthenozoospermia and evaluate the effect of YC on testicle and epididymis weight, sperm concentration, sperm motility, serum testosterone levels, and fertility rate. The results showed that YC significantly improved oligoasthenozoospermia induced by Ornidazole. Front Pharmacol. 2023 Apr 26;14:1056091.
Rats Asthenozoospermia model Oral 400 mg/kg Once daily for 14 consecutive days Induce asthenozoospermia in rats and evaluate sperm motility and function Theranostics. 2021 Jan 1;11(6):2822-2844

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01662765 - Completed - -
NCT00609973 Crohn's Disease Phase 2 Completed - United States, North Carolina ... More >> University of North Carolina Chapel Hill, North Carolina, United States, 27599 Less <<
NCT01662765 Pilonidal Sinus ... More >> Sinus; Dermal, Pilonidal Umbilical Granuloma Less << Not Applicable Completed - Turkey ... More >> Hatem Hospital Gaziantep, Turkey, 27090 Medical Park Gaziantep Hospital Gaziantep, Turkey, 27090 25 Aralık Familiy Physician Health Center Gaziantep, Turkey, 27100 Dr.Ersin Arslan State Hospital Gaziantep, Turkey, 27100 Şehitkamil State Hospital Gaziantep, Turkey, 27100 Less <<
NCT00609973 - Completed - -
NCT03491540 Rectal Cancer Surgery Phase 3 Not yet recruiting August 31, 2018 France ... More >> Service de chirurgie Colorectale / Hôpital Beaujon Not yet recruiting Clichy, Ile De France, France, 92110 Contact: Justine PROST A LA DENISE, MD    33 (0)1 40 87 45 47    justine.prostaladenise@aphp.fr    Contact: Yves PANIS, MD,PhD    33 (0)1 40 87 45 47    yves.panis@aphp.fr Less <<
NCT02618720 Elective Colorectal Surgery Phase 3 Unknown September 2017 France ... More >> CHU Clermont-Ferrand Recruiting Clermont-Ferrand, France, 63003 Contact: Patrick LACARIN    04 73 75 10 81    placarin@chu-clermontferrand.fr    Principal Investigator: Emmanuel FUTIER Less <<
NCT03475680 Colon Cancer Phase 3 Not yet recruiting August 31, 2021 France ... More >> Service de chirurgie Colorectale / Hôpital Beaujon Clichy, France, 92110 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.55mL

0.91mL

0.46mL

22.77mL

4.55mL

2.28mL

45.53mL

9.11mL

4.55mL

References

[1]Rutgeerts P, Van Assche G, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005 Apr;128(4):856-61.

[2]Goldstein EJ, Sutter VL, Finegold SM. Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob Agents Chemother. 1978 Oct;14(4):609-13.

[3]Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005 Apr;128(4):856-61. doi: 10.1053/j.gastro.2005.01.010. PMID: 15825069.

[4]Wei TT, Sun JH, Han LW, Chen K, Wang ZQ, Ji H. Effects of the ornidazole enantiomers on the central nervous system: Involvement of the GABAA receptor. Chem Biol Interact. 2015 Dec 5;242:163-9. doi: 10.1016/j.cbi.2015.09.019. Epub 2015 Sep 26. PMID: 26415617.

[5]Palmu A, Renkonen OV, Aromaa U. Ornidazole and anaerobic bacteria: in vitro sensitivity and effects on wound infections after appendectomy. J Infect Dis. 1979 May;139(5):586-9. doi: 10.1093/infdis/139.5.586. PMID: 220342.

[6]Tort S, Yıldız A, Tuğcu-Demiröz F, Akca G, Kuzukıran Ö, Acartürk F. Development and characterization of rapid dissolving ornidazole loaded PVP electrospun fibers. Pharm Dev Technol. 2019 Sep;24(7):864-873. doi: 10.1080/10837450.2019.1615088. Epub 2019 Jun 7. PMID: 31046546.

 

Historical Records

Categories